F-star Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FSTX research report →
About the company
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies.
- CEO
- Eliot Richard Forster
- IPO
- 2021
- Employees
- 84
- HQ
- Cambridge, GB
Price Chart
- Market Cap
- $156.51M
- P/E
- -3.79
- P/S
- 7.39
- P/B
- 1.22
- EV/EBITDA
- -3.10
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -145.10%
- Net Margin
- -147.79%
- ROE
- -44.74%
- ROIC
- -27.15%
- Revenue
- $21.17M · 88.05%
- Net Income
- $-31,283,000 · -22.11%
- EPS
- $-1.88 · 33.33%
- Op Income
- $-30,714,000
- FCF YoY
- -64.69%
- 52W High
- $7.12
- 52W Low
- $2.07
- 50D MA
- $5.63
- 200D MA
- $5.74
- Beta
- -0.35
- Avg Volume
- 747.28K
Get TickerSpark's AI analysis on FSTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 8, 23 | Kayitalire Louis | other | 29,236 |
| Mar 8, 23 | Kayitalire Louis | sell | 12,880 |
| Mar 8, 23 | Kayitalire Louis | sell | 25,019 |
| Mar 8, 23 | Kayitalire Louis | sell | 27,289 |
| Mar 8, 23 | Kayitalire Louis | sell | 35,719 |
| Mar 8, 23 | Kayitalire Louis | sell | 53,634 |
| Mar 8, 23 | Forster Eliot | other | 347,578 |
| Mar 8, 23 | Forster Eliot | sell | 165,028 |
| Mar 8, 23 | Forster Eliot | sell | 73,959 |
| Mar 8, 23 | Forster Eliot | sell | 127,924 |
Our FSTX coverage
Recent articles, reports, and earnings notes.
No research on FSTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FSTX report →Similar companies
Peers in the same neighborhood.